Ceftaroline as good as daptomycin for primary treatment for MRSA bloodstream infection
USA: In a new study, it was found that there was no difference in treatment failure or death between methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) treated with ceftaroline versus MRSA BSI treated with daptomycin. This study was conducted by Evan J Zasowski and the team, the results of which were published in the journal Open Forum Infectious Diseases.
Ceftaroline appears to be efficacious for MRSA BSI, although there are few comparable data with a standard of treatment. The results of MRSA BSI treated with ceftaroline versus daptomycin are compared in this study.
From 2010 to 2017, this was a multicenter, retrospective, observational cohort study of adult patients with MRSA BSI. Patients who had been given ceftaroline or daptomycin for less than 72 hours were included in the study. Those who cleared BSI before taking the trial medicine, as well as those who had a pneumonia cause, were excluded. The major outcome was composite treatment failure, which was defined as 30-day death, BSI duration of fewer than seven days on study medication, and MRSA BSI recurrence within 60 days. A 15% non-inferiority margin was applied to the inverse likelihood of treatment weighted risk difference in composite failure between the daptomycin and ceftaroline groups.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.